BCP
TEVA icon

BSN Capital Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

BSN Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,000,000
Closed -$50.7M – 20
2022
Q4 		$50.7M Buy
+6,000,000
New +$52.4M 3.59% 6

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

BSN Capital Partners's TEVA Position: Q1 2023 in Review

BSN Capital Partners sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2023, closing a stake of 6,000,000 shares — an estimated $50.7M sold.

BSN Capital Partners first reported a position in TEVA in Q4 2022 and held it in 1 quarter. The position peaked at $50.7M in Q4 2022. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

  • BSN Capital Partners reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2023 after selling out during the quarter.
  • BSN Capital Partners sold 6,000,000 Teva Pharmaceutical Industries Limited shares in Q1 2023, an estimated $50.7M.
  • BSN Capital Partners first reported a position in Teva Pharmaceutical Industries Limited in Q4 2022 and held it in 1 quarter.
  • BSN Capital Partners's Teva Pharmaceutical Industries Limited position peaked at $50.7M in Q4 2022.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2023.

Based on BSN Capital Partners's 13F filing for Q1 2023, filed 20 Apr 2023.